💸 The Tape

Decibel Cannabis Company (TSXV: DB) (OTCQB: DBCCF) reported record Q2 net revenue of $35.6 million, up 19% year-over-year, with record adjusted EBITDA of $7.8 million (+24%), record free cash flow of $4.9 million (+122%), and adjusted net income of $4.2 million (+23%).

Then it did the thing that separates this print from every other one this earnings season: it raised full-year guidance. Net revenue moves to $132–137 million from $130–135 million, and adjusted EBITDA to $28–32 million from $27–31 million.

Modest increases, granted. But in a cycle where Green Thumb's operating income fell by half, Verano's fell 88%, and MariMed set a revenue record while every profitability line deteriorated, a Canadian LP with a market cap most people can't name just told the market to expect more than it previously promised.

CEO Benjamin Sze framed it as momentum from last quarter translating into results. The segment data says it's more specific than that.

International is doing everything

International sales grew 72% year-over-year to a record $10.6 million. Domestic grew 6% to $25 million.

That gap explains the entire margin story. Gross margin before fair value adjustments improved to 51% from 47%, and management attributes the adjusted EBITDA increase primarily to international sales. Higher-margin export revenue growing twelve times faster than domestic revenue is what four points of gross margin expansion looks like.

The operational detail behind it is unusually concrete for a company this size. Decibel reports 16+ international customers with executed supply agreements, 50+ GACP cultivators onboarded under supply agreements, and 60 tons per annum of flower processing capacity running at roughly 34% utilization based on Q2 results.

Sit with that last figure. Two-thirds of the processing capacity is idle — and the company is already growing exports 72%. The incremental margin on filling that capacity is enormous, because the fixed cost is already absorbed.

Germany is the driver. Decibel cites improved German permit timelines as the source of initial growth, with reorders received for GMP-extracted product into that market, multiple finished vape SKUs added in the UK, and expanding EU GMP extract production shipping into multiple countries. The AgMedica EU GMP platform is described as performing well above the original underwriting case — an acquirer saying its acquisition beat the model, which is rare enough to note.

Management expects significantly high double-digit international growth through 2026, converting an existing backlog.

The competitive read

Everything in the international segment matters more when you look at who else is chasing it.

Every operator in North America has now identified export as the margin escape hatch. Curaleaf went hostile on Aurora specifically for its 50+ tons of EU-GMP capacity. SNDL just cleared an EU-GMP audit at Atholville hoping to reach where others already are. Village Farms grew exports 74% to $20.9 million. Organigram bought Sanity Group to get European distribution. Rubicon landed CUMCS and IMC-G.A.P. certifications for Cascadia. Tilray's international medical grew 34%.

Decibel is smaller than all of them and grew 72% with 66% of its processing capacity unused. It is not the biggest exporter, but it may have the most operating leverage per dollar of incremental export revenue in the entire cohort.

Domestic is holding, not growing

The Canadian business is fine, which in Canada counts as an achievement.

Market share stayed roughly flat at 4.3% on HiFyre data. General Admission remains the #1 infused pre-roll brand, with Decibel the #3 pre-roll LP overall heading into peak seasonality for that segment. The newer Standard Issue brand is scaling — now 6th in vapes at 2.9% share and 7th in infused pre-rolls at 2.8%.

Decibel is the #4 LP in vapes with year-to-date share growth of 0.9 points. General Admission holds #2 in liquid diamonds across both 510 and AIO formats — the fastest-growing vape segments — while Standard Issue holds #2 in distillate 1g 510.

Management reaffirms high single-digit domestic growth through 2026. Given that Canadian retail is contracting and SNDL just posted negative same-store comps across every consumer banner, holding share and growing 6% is a respectable outcome. It's just not where the story is.

The capital markets moves

Three announcements arrived alongside the numbers, and together they read as a company preparing to be taken seriously by institutions.

The share consolidation. Approved by shareholders back in December 2025, Decibel is proceeding with a 15-to-1 consolidation, reducing share count from 577,043,267 to approximately 38,469,551. Trading on the post-consolidation basis is expected on or about September 1, with a new CUSIP, subject to TSXV acceptance. Name and symbol unchanged.

The board's stated rationale is standard — higher price, better market image, institutional appeal, reduced volatility, improved liquidity, easier recruiting — and it explicitly cites consistent feedback received from shareholders. Note that Decibel joins Verano (1-for-5), TerrAscend (voting August 24), Ascend (voting August 28) and Vireo (30-to-1, done) in doing this within the same quarter. The whole sector is cleaning up its cap table at once.

The anticipated NCIB. Decibel is considering a buyback following the Q2 release and the consolidation, describing it as a constructive use of capital given its financial position. With $4.9 million of quarterly free cash flow, that's a defensible claim — considerably more so than Green Thumb spending 167% of operating cash flow on repurchases.

The board change. Chairman Shawn Dym becomes Executive Chairman, working more closely with management on capital allocation, M&A and long-term strategy, while Sze continues running day-to-day operations. Nadia Vattovaz becomes Lead Independent Director.

An executive chairman explicitly tasked with M&A, arriving the same day as a consolidation and a contemplated buyback, is not a coincidence. Decibel is signaling it intends to be an acquirer.

The read

Records across nearly every metric, guidance raised, margins expanding, free cash flow more than doubled, and two-thirds of processing capacity still available to fill.

The caveats are real: the guidance raise is small, domestic growth is single-digit in a contracting market, and 4.3% share makes Decibel a niche player at home. Adjusted EBITDA and free cash flow are both non-GAAP.

But the shape of this business — small, export-levered, underutilized, cash-generative — is exactly what everyone from Curaleaf to SNDL is currently paying up to build. Decibel already has it, and just told the market to expect more.

📈 Dog Walkers

$TSNDF ( ▲ 0.18% ) Renews Buyback

TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) has authorized a renewed normal course issuer bid to repurchase up to USD $10 million of common shares over twelve months, running August 24, 2026 through August 23, 2027.

Executive Chairman Jason Wild made the case directly: shares trade at a substantial discount to intrinsic value given the strength of the business, consistent operating and free cash flow generation, and emerging US industry catalysts. He specifically cited progress on federal reform and toward a major US exchange listing as strengthening conviction.

The cash flow claim holds up. TerrAscend posted its sixteenth consecutive quarter of positive operating cash flow in Q2, with $5.7 million of free cash flow and 54% gross margin. And notably, the company does not expect to incur debt to fund repurchases — a meaningful distinction after Green Thumb spent 167% of operating cash flow on buybacks last quarter.

Here's the context worth flagging. Under the previous NCIB, TerrAscend was authorized to buy 10 million shares and actually purchased 653,500 — about 6.5% of authorization — for roughly $417,371 at a volume weighted average of $0.64 per share.

The new authorization again covers up to 10 million shares, or 3.23% of the 309,175,647 outstanding as of August 13, with a daily cap of 58,784 shares (25% of average TSX volume). ATB Cormark returns as designated broker.

The timing is not accidental: shareholders vote August 24 on the share consolidation supporting an uplisting.

Buying back stock ahead of a consolidation and a listing is coherent. Whether TerrAscend deploys more than 6.5% of it this time is the actual test.

$VEXTF ( ▲ 9.85% ) Reports Q2

Vext Science (CSE: VEXT) (OTCQX: VEXTF) reported Q2 revenue of $12.1 million, essentially flat with Q1, as Ohio growth offset the planned Arizona cultivation wind-down. Beneath that flat line, the business got meaningfully better: adjusted EBITDA of $3.4 million, up 22% sequentially, with margin expanding to 28.3% from 23.1%, and net loss narrowing 79% year-over-year to $(0.3) million — essentially breakeven.

The strategic move is the story. Vext completed its Arizona cultivation wind-down in Q2 because, as the company puts it plainly, wholesale flower was selling below the cost of growing it. The Phoenix dispensaries now buy from third-party producers. CEO Eric Offenberger was blunt: capital came out of Arizona cultivation because the returns no longer cleared the hurdle, and it's being redeployed to Ohio retail, where incremental invested capital earns the highest available return.

That's a real decision, and a rare one. Most operators defend vertical integration long past the point where the arithmetic supports it.

The pricing experiment worked too. After sharpening prices in May, Central Phoenix posted its highest monthly customer count since October 2023, and Columbus weekly volumes hit first-half highs. Ohio yields improved to roughly 101 grams per plant, lowering shelf cost on product Vext stocks itself.

Ohio expansion continues: Fairfield opened in June as the sixth dispensary, a seventh arrives in Columbus by Q1 2027, and Vext remains on track for the state cap of eight in 2027. Ohio's SB 56 — which routed intoxicating hemp exclusively into licensed dispensaries — makes that footprint considerably more valuable than it looked a year ago.

Operating cash flow of $1.2 million looks soft against $4.2 million a year ago, but management attributes it to a deliberate Ohio inventory build ahead of second-half growth. Timing, not trend — plausible, though worth verifying next quarter.

The balance sheet moves are substantial for a company this size. Eloy is held for sale, with proceeds earmarked to retire associated secured debt by January 20, 2027 as a condition of extending the East West Bank note. And on August 19, Vext closed roughly $17.0 million with Wright-Patt Credit Union — refinancing $10.3 million of existing debt and acquiring the Jackson Property outright for $6.0 million, giving it full ownership of its 50-acre Ohio cultivation site at 8.64% fixed.

Small, disciplined, and pointed entirely at the right state.

📺 Trade To Black

Cannabis Medical Markets Are Growing, So What's Next? | TDR Cannabis in 5

• Organigram posts a record quarter. CEO James Yamanaka joins Shadd Dales to break down Q3 fiscal 2026: net revenue of $105.8 million, up 49% year-over-year, with adjusted EBITDA surging 136% to $13.4 million — driven largely by the newly consolidated Sanity Group in Germany, contributing roughly €25 million in net revenue.

• Canadian market leadership holds. Organigram remains the top overall share position in Canada, leading in vapes and milled flower with strong placements across concentrates, flower and pre-rolls.

• Europe, EU-GMP, and the Curaleaf-Aurora fallout. James covers European expansion progress and the EU-GMP certification update for Moncton, plus his take on Curaleaf's (TSX: CURA) hostile bid for Aurora (NASDAQ: ACB) — which drove a flurry of volume through Canadian LPs including Organigram — and where he sees sector M&A heading.

• Adam Stettner on emerging medical markets. The FundCanna CEO returns for his weekly appearance to discuss patient growth in newer states like Georgia and Kentucky post-rescheduling, and what's actually driving lending demand on the medical side right now.